Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 13/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 6/20 | 1.00 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26934770 | 0.99 | P2RY1 (0.98) | P2RY1P2RY2P2RY11ADORA3P2RY4 | |
| SCHEMBL21710863 | 0.99 | P2RY1 (0.98) | P2RY1P2RY2P2RY11ADORA3P2RY4 | |
| SCHEMBL19503289 | 0.92 | P2RY1 (0.85) | P2RY1P2RY2P2RY11ADORA3 | |
| SCHEMBL19807529 | 0.92 | P2RY1 (0.84) | P2RY1P2RY2P2RY11ADORA3 | |
| SCHEMBL19464971 | 0.91 | P2RY1 (0.83) | P2RY1P2RY2P2RY11ADORA3 | |
| SCHEMBL19459473 | 0.88 | P2RY1 (0.83) | P2RY1P2RY2P2RY11ADORA3P2RY4 | |
| SCHEMBL19503293 | 0.87 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3 | |
| SCHEMBL19459517 | 0.87 | P2RY1 (0.82) | P2RY1P2RY2P2RY11ADORA3P2RY4 | |
| SCHEMBL29317531 | 0.87 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3 | |
| SCHEMBL19503936 | 0.87 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | P2RY1 113/4885P2RY2 119/4885P2RY11 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.